AI 资本情报
Alexandria Venture Investments · 机构档案
机构速览
Alexandria Venture Investments 是 Alexandria Real Estate Equities, Inc. 的战略风险投资平台。该公司新闻稿称平台自1996年起投资生命科学、农业食品科技、气候与技术企业；截至2021年底，众多组合公司的已实现和未实现回报超过10倍（公司自述）。2026年BigHat Biosciences公告将其列为Series C现有投资方之一。
来源核验日期： · 本档案包含官网、本人公开资料或一手披露核验内容；详细来源和原文摘录见下方。
本库收录的融资关联
- BigHat Biosciences2026-09-24 · C轮 · 7500 万美元
关联仅表示收录记录中的参与，不代表完整投资组合或投资收益。
基本信息
| 机构类型 | Alexandria Real Estate Equities, Inc. 的战略风险投资平台 来源 1 |
|---|---|
| 平台创立年份 | 1996 来源 2 |
| 投资领域 | 生命科学、农业食品科技、气候变化、科技 来源 2 |
发展节点
- 1996
公司资料称平台自1996年起开展战略投资。 来源 2
公开成绩与记录
- Alexandria官方投资者关系新闻稿称，截至2021年12月31日，众多组合公司的已实现和未实现回报超过10倍；这是公司披露口径，并非当前基金整体净回报。 来源 3
- BigHat Biosciences于2026年9月24日发布的Series C融资公告将Alexandria Venture Investments列为现有投资方之一。 来源 4
- 融资来源记录：BigHat Biosciences · C轮 · 2026-09-24 · 本轮参投 · $75 million。这是本库收录的披露案例，不代表完整投资组合。 来源 5
原始来源
- 1. Alexandria Venture Investments Achieves Fifth Consecutive Annual #1 Most Active Corporate Investor in Biopharma
Alexandria Venture Investments, the strategic venture capital platform of Alexandria Real Estate Equities, Inc.
- 2. Alexandria Venture Investments Achieves Fifth Consecutive Annual #1 Most Active Corporate Investor in Biopharma
Since its inception in 1996, Alexandria Venture Investments has strategically invested in disruptive life science, agrifoodtech, climate change and technology companies.
- 3. Alexandria Venture Investments Achieves Fifth Consecutive Annual #1 Most Active Corporate Investor in Biopharma
As of December 31, 2021, the platform's deep track record has enabled Alexandria Venture Investments to generate realized and unrealized returns in excess of 10x for numerous portfolio companies that are working across infectious diseases, neuroscience, oncology and next-generation medicines platforms.
- 4. BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
The round was co-led by DFJ Growth & Premji Invest with participation from Catalio Capital Management, LG Technology Ventures, Sigmas Group, and existing investors including 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz (a16z), Discovery Ventures, GRIDS Capital, Intermountain Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund, Quadrille Capital, and Section 32.
- 5. BigHat Biosciences 宣布完成 7500 万美元 C 轮融资，以推进 AI 设计的治疗药物和领先的智能体数据平台，用于快速蛋白质设计
existing investors including 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz (a16z), Discovery Ventures, GRIDS Capital, Intermountain Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund, Quadrille Capital, and Section 32.